# Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

> **NCT03740256** · PHASE1 · RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 45 (estimated)

## Conditions studied

- Bladder Cancer
- Head and Neck Squamous Cell Carcinoma
- Cancer of the Salivary Gland
- Lung Cancer
- Breast Cancer
- Gastric Cancer
- Esophageal Cancer
- Colorectal Cancer
- Pancreatic Adenocarcinoma
- Solid Tumor

## Interventions

- **BIOLOGICAL:** CAdVEC

## Key facts

- **NCT ID:** NCT03740256
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-14
- **Primary completion:** 2026-12-30
- **Final completion:** 2038-12-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03740256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03740256, "Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03740256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*